Important advances have been achieved using 11C-UCB-J PET binding to the synaptic vesicle glycoprotein 2A (SV2A) to measure synaptic density in vivo across neurodegenerative disorders, showing consistent patterns of SV2A loss in AD and PD, partly overlapping with hypometabolism [143]. This evidence concerns the gene SV2A and Alzheimer disease.